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Rational Inferences about Departures from Hardy-Weinberg Equilibrium
Jacqueline K. Wittke-Thompson,1 Anna Pluzhnikov,1 and Nancy J. Cox1,2
Departments of 1Human Genetics and 2Medicine, The University of Chicago, Chicago
Previous studies have explored the use of departure from Hardy-Weinberg equilibrium (DHW) for fine mapping
Mendelian disorders and for general fine mapping. Other studies have used Hardy-Weinberg tests for genotyping
quality control. To enable investigators to make rational decisions about whether DHW is due to genotyping error
or to underlying biology, we developed an analytic framework and software to determine the parameter values for
which DHW might be expected for common diseases. We show analytically that, for a general disease model, the
difference between population and Hardy-Weinberg–expected genotypic frequencies (D) at the susceptibility locus
is a function of the susceptibility-allele frequency (q), heterozygote relative risk (b), and homozygote relative risk
(g). For unaffected control samples, D is a function of risk in nonsusceptible homozygotes (a), the population
prevalence of disease (KP), q, b, and g. We used these analytic functions to calculate D and the number of cases or
controls needed to detect DHW for a range of genetic models consistent with common diseases (1.1  g  10
and 0.005  KP  0.2). Results suggest that significant DHW can be expected in relatively small samples of patients
over a range of genetic models. We also propose a goodness-of-fit test to aid investigators in determining whether
a DHW observed in the context of a case-control study is consistent with a genetic disease model. We illustrate
how the analytic framework and software can be used to help investigators interpret DHW in the context of
association studies of common diseases.
Introduction
Hardy-Weinberg equilibrium (HWE) has been used for
more than a century to better understand genetic char-
acteristics of populations. In 1902, William E. Castle
noted that, if the selective removal from the general pop-
ulation of individuals who have a recessive genotype at
a particular locus ceases, then the future generation will
establish an equilibrium value of recessive alleles. His
conclusions assume that one allele is dominant with re-
spect to the other(s), that the alleles do not affect fertility,
that there is no migration into or out of the population,
and that the population is large and randomly mating
(Castle 1903; Li 1967). Five years later, G. H. Hardy
and W. Weinberg individually came to the same conclu-
sion but noted that the population allele frequencies
could be used to calculate the equilibrium-expected ge-
notypic proportions (Hardy 1908; Weinberg 1908). If p
is the frequency of one allele (A) and q is the frequency
of the alternative allele (a) for a biallelic locus, then the
HWE-expected frequency will be for the AA ge-2p
notype, 2pq for the Aa genotype, and for the aa2q
genotype. The three genotypic proportions should sum
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to 1, as should the allele frequencies (Hardy 1908; Wein-
berg 1908).
The most common way to assess HWE is through a
goodness-of-fit x2 test (Weir 1996). The null hypothesis
is that alleles are chosen randomly, and the genotypic
proportions thus follow HWE-expected proportions
(i.e., p2, 2pq, and q2). Alternatively, the second allele is
dependent on the first allele being selected, resulting in
the genotypic proportions deviating from the HWE-
expected proportions. The x2 test for HWE has k(k
df, where k is the number of alleles at the locus1)/2
being studied (Weir 1996). Or, more intuitively, the de-
grees of freedom can be calculated by , where g isg k
the number of possible genotypes and k is the number
of alleles. For example, a SNP that has two alleles
and three possible genotypes yields 1 df for the x2 test
that assesses the significance of departure from HWE
(DHW).
Testing for HWE is commonly used for quality con-
trol of large-scale genotyping and is one of the few ways
to identify systematic genotyping errors in unrelated
individuals (Gomes et al. 1999; Hosking et al. 2004).
However, there is little consensus on the correct thresh-
old for identifying DHW in the context of large-scale
studies or on what to do with markers that fit all other
quality-control criteria but show a significant DHW,
given the study-specific threshold. Some association
studies do not consider DHW in patients to indicate
genotyping error but prefer to assume a biological ex-
planation for DHW in a patient sample, while requiring
968 Am. J. Hum. Genet. 76:967–986, 2005
control or random samples to be in HWE (Oka et al.
1999; Levecque et al. 2003; Nejentsev et al. 2003). Oth-
ers require that both the patient and the control samples
be in HWE for the marker to be used in further analyses
(Martin et al. 2000; Xu et al. 2001; Wang et al. 2003).
Bonferroni correction is commonly used to correct for
multiple testing when many markers are tested for HWE
but is a conservative approach if the markers are cor-
related (e.g., are in linkage disequilibrium [LD]). An-
other widespread approach is to assign a significance
level, such as 5% or 1%, and to test each marker with-
out regard for whether markers are independent. Some-
times, markers showing DHW are removed from a data
set because subsequent genetic analysis requires HWE
to be assumed. However, since the design of association
studies is to partition cases and controls in the general
population on the basis of their phenotype and genetic
composition, cases and controls at a disease locus may
be expected to show DHW under certain conditions.
There is little guidance on how to distinguish between
markers whose DHW is due to chance, genotyping er-
ror, or failure of one of the requisite assumptions of
HWE from markers whose DHW is due to their prox-
imity to an allele affecting a phenotype on which the
sample is ascertained (Xu et al. 2002).
Our focus is to understand DHW observed in the
context of association studies. When an investigator ob-
serves a marker with a significant DHW, a key question
is “Are deviations from HWE due to genotyping error,
chance, failure of assumptions underlying Hardy-Wein-
berg expectations, or, instead, to the underlying genetic
disease model?” To address this question, we developed
an analytic framework for assessing the difference be-
tween population and HWE-expected genotypic pro-
portions (D), as well as software tools for calculating
expectations over a range of single-locus genetic disease
models. We use a single-locus context in our exami-
nation of DHW because it enables us to represent the
marginal effects of the particular susceptibility locus be-
ing examined. For general disease models, we show that
D in patients at the disease locus is determined by the
population susceptibility-allele frequency (q), the ho-
mozygote relative risk (g), and the heterozygote rela-
tive risk (b). For “true” control samples (i.e., those as-
certained by being unaffected with respect to disease
status), the value of D depends on the risk to nonsus-
ceptible homozygotes (a), q, g, and b. Using these for-
mulations, we have examined a wide range of parameter
values for genetic models commonly believed to be con-
sistent with observations for complex disorders. Our
results provide support for the notion that systematic
examination of HWE has been underutilized as a tool
for fine mapping. To aid investigators in distinguishing
a DHW that is generated by the biological model un-
derlying disease transmission from one that is generated
by genotyping errors, chance, or failure of the requisite
assumptions of HWE, we propose a general goodness-
of-fit test to determine whether the observed genotype
counts are significantly different from the expected ge-
notype counts in patients and controls for the genetic
disease model that best fits the observed data. We pro-
vide software for both the investigation of DHW in a
generalized single-locus context and the examination of
specific observations of DHW.
Methods
Common Disease Models
The prevalence of disease in the general population is
defined as , where p is the2 2K p p a 2pqab q agP
population frequency of the wild-type allele (A), q is the
frequency of the disease-susceptibility allele (a), and a
is the baseline penetrance of disease in homozygotes
without a risk allele at this locus. By modeling the pop-
ulation prevalence of disease in the general population
in this manner, we explicitly assume that the suscepti-
bility locus will be in HWE in the general population.
Note that, although this parameterization is for a single-
locus model, there may be many genetic and nongenetic
risk factors, in addition to the particular region being
studied, that will determine values of the parameters a,
b, and g. Thus, we use this approach to model the mar-
ginal effects of a particular model, with the full recog-
nition that, in general, there will be nongenetic risk fac-
tors and many other loci with genetic variation that
affect the phenotype.
We explored dominant, recessive, additive, and mul-
tiplicative genetic models with KP and g values that are
characteristic of a variety of common diseases, for which
KP values range from 0.005 to 0.2 and g is equal to 1.1,
1.3, 1.5, 2, 5, or 10. All dominant, recessive, and ad-
ditive models examined correspond to sibling relative
risk (ls) values !2.5, although most models have l s
. Multiplicative models generally have higher ls val-1.1
ues than dominant, recessive, and additive models with
identical parameters. The maximum ls for a multipli-
cative model is 4.20, which occurs at the lowest popu-
lation prevalence ( ) and the highest homo-K p 0.005P
zygote relative risk ( ), but most multiplicativegp 10
models considered have ls values !1.2.
The Difference between Population and Expected
Genotypic Frequencies (D)
Weir (1996) defined a variable, D, as the difference
between population and HWE-expected genotypic fre-
quencies. D is population specific (e.g., Dp for patients
and for unaffected controls), and it ranges fromD c
to .2 2 2max [(1 q) ,  q ] (q q )
To better understand the magnitude and direction of
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DHW for different genetic disease models, we defined
D in terms of key parameters of the genetic model, spec-
ified separately in patients and controls, and character-
ized how parameters interact to affect directionality of
DHW (i.e., if , there is a deficiency of homozygotesD ! 0
and an excess of heterozygotes; if , there is an ex-D 1 0
cess of homozygotes and a deficiency of heterozygotes).
For patients in a general disease model,
2 2 2q (1 q) (g b )
D p . (1)p 2 2 2[(1 q)  2q(1 q)b q g]
A more thorough derivation of the above equation and
the simplified equations for the classic dominant, reces-
sive, and additive models are given in appendix A. For
a multiplicative model, Dp is equal to 0 and there is no
expected DHW. Figure 1 highlights the direction and
magnitude of Dp as the susceptibility-allele frequency at
the susceptibility locus varies from 0 to 1.
Similarly, for an unaffected control sample,
2 2 2aq (1 q) (2b 1 g ab  ag)
D p , (2)c 2(1 K )P
and equations for the classic recessive, classic dominant,
additive, and multiplicative models are given in appen-
dix B. Figure 2 shows the direction and magnitude of
Dc for several dominant, recessive, additive, and multi-
plicative models.
Number of Individuals Needed to Detect DHW
The x2 test of HWE for patients can be simplified to
the following:
2ˆN Dp p2x p , (3)p 2 2
ˆ ˆq (1 q )p p
where is the number of patients and is the sus-ˆN qp p
ceptibility-allele frequency estimated in patients (Weir
1996). A x2 value can also be determined for controls
by using the susceptibility-allele frequency in controls
( ), , and the number of controls in the sampleqˆ Dc c
(Nc). The power of the x
2 test can be accounted for by
using a noncentral x2 distribution with noncentrality
parameter
2ˆND
up 2 2
ˆ ˆq (1 q)
(Weir 1996).
Given the above equations, it is straightforward to
determine the number of individuals required to detect
DHW for a specified level of significance and power, for
patients and controls under any disease model. In figure
3, results for a variety of models are graphed in terms
of Np or Nc and the overall susceptibility-allele frequency
for patients or controls. The results presented in figure
3A (patients) and 3B (controls) use a central x2 distri-
bution corresponding to a significance level of 5% and
50% power, and the results presented in figure 3C (pa-
tients) and 3D (controls) use a noncentral x2 distribution
corresponding to a significance level of 5% and 80%
power.
For congruence with other studies reporting the results
in terms of ls, the risk of disease in siblings of an affected
individual relative to the risk in the general population,
are summarized in appendix C with respect to common
disease models. We also summarize results with respect
to ls and D in figure 4.
Goodness-of-Fit Test
Given the analytic framework characterized above
and a set of observations in patients and controls with
DHW in one or both samples, we proceed to identify
the genetic disease model with the best fit to the geno-
typic proportions observed in patients and controls (con-
strained by the known lifetime prevalence of disease). If
that “best-fit” model is, nevertheless, a poor fit to the
observed data, as assessed by a x2 test with 1 df for a
general model and 2 df for a restrictive (dominant, re-
cessive, additive, or multiplicative) model (see appendix
D), then it is unlikely that the underlying genetic disease
model has generated the observed DHW; thus, alter-
native explanations for the DHW, including chance, ge-
notyping error, and/or violations of the requisite as-
sumptions of HWE, must be considered.
Examples
We chose several examples from the literature that
illustrate how our results and software can help inves-
tigators distinguish a DHW consistent with genetic mod-
els from one that is not. The first example involves a
DHW in patients but not in controls, with data derived
from an association study of Crohn disease and a rare
frameshift polymorphism (Leu3020fsinsC) in CARD15/
NOD2 (Ogura et al. 2001; J. Cho, personal commu-
nication). The second example includes data from an
association study that identified a highly significant as-
sociation ( ) between LTA and myocar-6Pp 3.3# 10
dial infarction (MI) (Ozaki et al. 2002), attributable in
part to the effect of significant DHW in both patients
and controls in opposite directions. We also took ad-
vantage of several recent surveys of polymorphisms with
DHW (Xu et al. 2002; Gyo¨rffy et al. 2004; Kocsis et al.
2004a, 2004b; Osawa et al. 2004) to determine the pro-
portion that are consistent with a genetic disease model
(table 1).
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Figure 1 Dp plotted versus the susceptibility-allele frequency for patients. A, B, and D, Data points are as follows: (blackenedgp 1.1
diamonds), (unblackened triangles), (blackened triangles), (unblackened diamonds), (blackened squares), andgp 1.3 gp 1.5 gp 2 gp 5
(unblackened circles). A, Dominant model. B, Recessive model. C, Additive model. Since would not satisfy our definition of angp 10 g ! 2
additive model as and , the data points in C are as follows: ( ) (blackened diamonds), ( ) (unblackenedgp 2b b 1 1 gp 2.2 bp 1.1 gp 2.6 bp 1.3
triangles), ( ) (blackened triangles), (blackened squares), (unblackened diamonds). D, Multiplicative model.gp 3 bp 1.5 gp 5 gp 2
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Figure 2 Dc plotted versus the susceptibility-allele frequency for controls. A, B, and D, Data points are as follows: (blackenedgp 1.1
diamonds), (unblackened triangles), (blackened triangles), (unblackened diamonds), (blackened squares), andgp 1.3 gp 1.5 gp 2 gp 5
(unblackened circles). A, Dominant model, . B, Recessive model, . C, Additive model, . As in figure 1,gp 10 K p 0.1 K p 0.2 K p 0.01P P P
because of our definition of an additive model ( and ), the data points in C are as follows: ( ) (unblackened diamonds),gp 2b b 1 1 gp 4 bp 2
( ) (blackened diamonds), ( ) (unblackened triangles), ( ) (blackened triangles), (unblackenedgp 2.2 bp 1.1 gp 2.6 bp 1.3 gp 3 bp 1.5 gp 2
diamonds), (blackened squares), and (unblackened circles). D, Multiplicative model, .gp 5 gp 10 K p 0.05P
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Figure 3 A, Number of patients needed to detect DHW as the susceptibility-allele frequency changes at a significance level of 5% and
50% power. Data points are as follows: dominant model with (unblackened triangles), dominant model with (unblackenedgp 1.3 gp 10
circles), recessive model with (blackened triangles), recessive model with (unblackened diamonds), additive model withgp 1.5 gp 2 gp
(blackened diamonds), and additive model with (blackened squares). B, Number of controls needed to detect DHW as the susceptibility-2.2 gp 5
allele frequency changes at a significance level of 5% and 50% power. Data points are as follows: dominant model with andK p 0.2 gpP
(blackened circles), recessive model with and (blackened circles), recessive model with and (unblackened10 K p 0.05 gp 10 K p 0.2 gp 5P P
squares), additive model with and (blackened squares), multiplicative model with and (blackened squaresK p 0.2 gp 5 K p 0.1 gp 10P P
with white cross), and multiplicative model with and (blackened squares with white star). C, Same data points as A but assessedK p 0.2 gp 5P
at 80% power. D, Same data points as B but assessed at 80% power.
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Figure 4 Sibling relative risk for dominant models with and varied g values: (unblackened circles), (blackenedK p 0.2 gp 10 gp 5P
squares), (unblackened diamonds), and (blackened triangles).gp 2 gp 1.5
Results
Magnitude of D
As noted elsewhere, the larger the value of D, the more
the genotypic frequency departs from HWE expectations
(Weir 1996). In patients, the magnitude of Dp is deter-
mined by q, g, and b, as shown in equation (1) above.
The maximum value for Dp, given a genetic disease
model, occurs at the susceptibility-allele frequency that
maximizes the HWE-expected proportion of heterozy-
gotes affected with disease (gAa) and can be calculated
by
2g b 2D p g .p Aa24b
For example, the maximum Dp for a dominant model
with occurs when the allele frequency is 0.45,gp 1.5
which corresponds to the highest proportion of HWE-
expected heterozygotes among patients ( )g p 0.5505Aa
under this model.
In controls, Dc is a function of KP, a, b, g, and q.
Larger Dc values occur as the prevalence of disease in
the general population increases, whereas, in patients,
KP has no direct effect on the size of Dp. For example,
a dominant model with and leads togp 1.5 qp 0.33
a Dc of 0.00209 when and a Dc of 0.000193K p 0.1P
when . Larger Dc values also occur with higherK p 0.01P
g values, as shown in figure 2. The susceptibility-allele
frequency also affects the magnitude of , with com-D c
mon allele frequencies ( ) corresponding0.1  q  0.8
to larger Dc values and with allele frequencies at the tails
of the frequency spectrum corresponding to smaller Dc
values.
Direction of D
The direction of D is vital to understanding whether
an observed DHW can be due to the underlying genetic
model, and, for patients, the disease model specifies the
direction of Dp (table 2). The additive model is different
than the dominant, recessive, or multiplicative models,
in that Dp can be positive, negative, or zero. Dp is positive
when 2 ! g ! 4 and negative when . However, wheng 1 4
, the additive model is equivalent to the multipli-gp 4
cative model ( and ), and Dp is equal to 0bp 2 gp 4
(i.e., no DHW is expected). The general model is de-
pendent on the value associated with b, where Dp is
positive if and negative if .2 2g 1 b g ! b
The direction of D in controls is also dependent on
the underlying genetic disease model, and, for dominant
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and recessive models, Dc is in the direction opposite that
observed in patients. Interestingly, Dc for controls under
the additive model does not change with g, as observed
for patients, but always shows an excess of heterozygotes
( ). However, there is an asymmetry in the ho-D ! 0c
mozygote classes when for both patients and con-D( 0
trols, with patients showing an excess of disease-suscep-
tible homozygotes and controls showing an excess of
wild-type homozygotes. The multiplicative model gen-
erates D values for controls similar to those generated
by the recessive and additive models, with . TheD ! 0c
direction of DHW for a general disease model in controls
is negative if and positive if the2g 1 ab 1 2b ag
inequality is reversed (i.e., ).2g 1 ab ! 2b ag
Number of Individuals Needed to Detect DHW for a
Specified Significance and Power
As might be expected, fewer patients are needed to
detect DHW as the genotype relative risk increases. It is
notable, however, that low g values (e.g., 1.5) can pro-
duce DHW with relatively small samples of patients. For
example, !500 patients are needed to detect DHW (at
a significance level of 5% and 50% power) under a
recessive model with and over a range of sus-gp 1.5
ceptibility-allele frequencies from 0.29 to 0.63. As g in-
creases to 2, the range of susceptibility-allele frequencies
increases to 0.11–0.81, with a minimum sample size of
∼130 patients when with 50% power (fig. 3A)qp 0.4
and 267 patients with 80% power (fig. 3C). An additive
model, however, requires a minimum of ∼750 patients
at to detect DHW with , but the requiredqp 0.38 gp 3
sample size decreases to 176 patients with . Asgp 2.2
shown above, Dp increases for additive models as in-g
creases or decreases from 4. Therefore, at a significance
level of 5% and 50% power, an additive model can lead
to detection of DHW in 176 patients when either gp
or . The difference between the two ob-2.2 gp 7.56
servations, however, is the direction of the DHW, in
which the former ( ) shows an excess of homo-gp 2.2
zygotes and the latter ( ) shows a deficiency ofgp 7.56
homozygotes.
The number of controls needed to detect DHW is
generally much larger but is often still within the range
of commonly collected sample sizes for a wide range of
models. As with patients, the number of controls re-
quired to detect DHW decreases as g increases. But,
unlike in the calculations for patients, KP also determines
the number of controls needed to detect DHW. For dom-
inant models, !1,000 unaffected individuals are needed
to detect DHW when and with 50%K p 0.2 g  5P
power (fig. 3B), and !2,000 controls with 80% power
(fig. 3D). Because of the specifications of the additive
model, the same effect is observed in controls as in pa-
tients, whereby a decrease in the number of controls
needed to detect DHW occurs as g increases or decreases
from 4. Recessive models with can lead to detec-g  5
tion of DHW in !200 controls with 50% power when
. When KP decreases to as low as 0.05, ∼1,000K p 0.2P
controls are needed to detect DHW for the recessive
model with and (fig. 3B). Multipli-g  10 qp 0.23
cative models show DHW in a sample of !2,000 controls
when and and in a sample of !1,200K  0.1 g  10P
controls when and (at 50% power andK  0.2 g  5P
a significance level of 5%). Generally, larger Dc values
are associated with models specified by high KP values
(e.g., ) and high g values (e.g., ).K  0.2 g  5P
Sibling Relative Risk Values that Correspond to
Expected DHW
We calculated ls for all models studied, to understand
the results for these common disease models relative to
those of previous studies that assessed power by using
this parameter. As expected, ls increases as KP decreases,
and, overall, the resulting ls values (including those that
are expected to give DHW in a small sample) are quite
small. For dominant models or recessive models (gp
), in which DHW is expected for samples of !5001.5
patients, ls is !1.03 (fig. 4). For additive models, in
which !1,400 patients are needed to detect DHW, ls
values do not exceed 1.18. Thus, DHW can be observed
for strikingly low ls values in sample sizes currently be-
ing used for large-scale association studies.
Example 1: DHW in Patients Only
Ogura et al. (2001) conducted a case-control associ-
ation study of Crohn disease to fine map IBD1 in the
pericentromeric region of chromosome 16. They iden-
tified a cytosine insertion (Leu3020fsinsC) in CARD15/
NOD2 that causes a truncated NOD2 protein and that
results in deficient activation of NF-kB and the immune
response. We calculated HWE for the Leu3020fsinsC
(Cins) polymorphism in unrelated Jewish and European
American patients with Crohn disease and in unrelated
controls. Because of the low proportion of HWE-ex-
pected homozygotes, we used Fisher’s exact test to
determine DHW (Weir 1996). The distribution of ge-
notypes in Jewish patients was 121 wild-type (wt)/wt
homozygotes, 15 Cins/wt heterozygotes, and 4 Cins/Cins
homozygotes, which yields . The genotypePp .0059
distribution in European American patients was 314 wt/
wt homozygotes, 41 Cins/wt heterozygotes, and 9 Cins/
Cins homozygotes. Fisher’s exact test generates Pp
, which is also highly significant. When all41.28# 10
unrelated patients are tested for DHW (456 wt/wt ho-
mozygotes, 61 Cins/wt heterozygotes, and 13 Cins/Cins
homozygotes), . All three populations6Pp 6.83# 10
of patients showed significant DHW, with an excess of
homozygotes. The distribution of genotypes in all con-
978
Ta
bl
e
1
Su
rv
ey
of
D
H
W
PU
B
M
E
D
ID
D
IS
E
A
SE
a
G
E
N
E
G
E
N
O
T
Y
P
E
D
IS
T
R
IB
U
T
IO
N
Sb
K
P
q
a
b
g
x
2
P
c
Pa
ti
en
ts
C
on
tr
ol
s
12
22
11
72
A
lz
he
im
er
di
se
as
e
A
2M
61
-4
8-
23
98
-7
7-
9
.0
6
.2
64
.0
51
3
1.
08
5
2.
96
6
1.
01
6
N
S
12
10
53
08
A
lz
he
im
er
di
se
as
e
A
P
O
E
4-
18
-9
4
6-
53
-7
4
.0
6
.7
58
.0
26
9
1.
00
0
3.
13
7
1.
01
3
N
S
12
10
53
08
A
lz
he
im
er
di
se
as
e
A
P
O
E
31
-4
9-
29
67
-1
02
-1
9
.0
6
.3
81
.0
44
9
1.
25
1
2.
50
9
4.
22
1
.0
40
12
10
53
08
A
lz
he
im
er
di
se
as
e
A
P
O
E
57
-1
18
-1
00
58
-9
7-
48
.0
6
.4
82
.0
46
2
1.
11
8
2.
02
7
.5
47
N
S
12
10
53
08
A
lz
he
im
er
di
se
as
e
A
P
O
E
12
0-
36
1-
19
4
20
6-
30
9-
14
2
.0
6
.4
58
.0
36
2
1.
79
1
2.
26
5
1.
48
5
N
S
11
07
47
89
A
lz
he
im
er
di
se
as
e
C
ST
3
32
2-
16
6-
29
26
0-
12
4-
6
.0
5
.1
79
.0
46
3
1.
17
4
1.
91
3.
91
4
.0
48
11
46
83
25
A
lz
he
im
er
di
se
as
e
C
ST
3
14
0-
33
-6
17
9-
43
-6
.0
6
.1
21
.0
59
1.
00
0
2.
11
4
4.
06
4
N
S
11
46
83
25
A
lz
he
im
er
di
se
as
e
C
ST
3
13
7-
34
-8
18
0-
40
-8
.0
6
.1
3
.0
58
7
1.
00
0
2.
34
3
9.
67
1
.0
08
12
03
48
04
A
lz
he
im
er
di
se
as
e
IL
-1
b
5-
40
-3
9
15
-1
07
-9
5
.0
6
.6
79
.0
36
5
1.
71
8
1.
71
8
4.
81
2
N
S
10
86
98
06
A
lz
he
im
er
di
se
as
e
IL
-6
pr
om
ot
er
11
0-
14
8-
44
34
-2
2-
12
.0
5
.3
5
.0
43
1.
25
7
1.
37
7
5.
11
1
.0
24
10
81
51
36
A
lz
he
im
er
di
se
as
e
P
S1
3-
45
-4
5
3-
24
-1
8
.0
5
.6
6
.0
14
1
3.
80
3
3.
94
1.
92
9
N
S
11
12
42
96
M
ac
ul
ar
de
ge
ne
ra
ti
on
m
E
P
H
X
42
-2
4-
32
95
-3
8-
33
.0
1
.3
26
.0
07
67
1.
00
0
3.
87
4
40
.4
23
K
.0
01
10
84
31
85
A
ut
oi
m
m
un
e
hy
po
th
yr
od
is
m
IL
-4
2-
7-
68
3-
23
-7
5
.0
2
.8
47
.0
09
17
1.
00
0
2.
64
5
2.
90
9
N
S
10
78
16
45
A
cu
te
m
yo
ca
rd
ia
l
in
fa
rc
ti
on
5-
H
T
2A
re
ce
pt
or
39
-1
33
-8
3
43
-1
50
-6
2
.0
5
.5
38
.0
36
2
1.
43
5
1.
56
8
8.
82
9
.0
03
11
78
14
17
B
le
ph
ar
os
pa
sm
D
1.
1
25
-5
1-
15
42
-3
2-
16
.0
01
.3
61
.0
00
67
3
1.
80
4
1.
87
5
4.
48
5
.0
34
11
14
24
20
B
re
as
t
ca
nc
er
C
Y
P
17
39
-6
3-
10
11
2-
13
2-
33
.0
5
.3
52
.0
41
2
1.
36
7
1.
36
7
3.
16
1
N
S
10
69
84
74
B
re
as
t
ca
nc
er
C
Y
P
1B
1
37
-1
01
-4
8
44
-1
27
-2
9
.0
5
.4
68
.0
35
7
1.
50
4
1.
67
8
15
.7
36
7.
3
#
10

5
10
69
84
74
B
re
as
t
ca
nc
er
C
Y
P
1B
1
26
-6
8-
27
26
-7
8-
17
.0
5
.4
64
.0
37
9
1.
44
6
1.
44
6
11
.1
1
.0
04
10
69
84
74
B
re
as
t
ca
nc
er
C
Y
P
1B
1
11
-3
2-
21
18
-4
9-
12
.0
5
.4
69
.0
30
9
1.
59
9
2.
46
4.
77
4
.0
29
11
15
63
91
C
an
ce
r
to
xi
ci
ty
(i
ri
no
te
ca
n)
U
G
T
1A
1
14
-8
-4
79
-1
0-
3
.0
1
.1
16
.0
06
95
2.
22
1
15
.1
1
7.
94
7
.0
05
12
78
74
24
C
hr
on
ic
al
lo
gr
af
t
ne
ph
ro
pa
th
y
T
G
F-
b
1
0-
22
-8
23
-8
3-
67
.0
1
.6
13
0
11
.7
6
11
.7
6
4.
20
4
N
S
12
78
74
24
C
hr
on
ic
al
lo
gr
af
t
ne
ph
ro
pa
th
y
T
N
Fa
50
-2
4-
1
13
2-
31
-1
0
.0
1
.1
64
.0
09
49
1.
17
9
1.
17
9
13
.5
77
.0
01
10
50
44
87
C
hr
on
ic
re
na
l
fa
ilu
re
V
D
R
34
-1
18
-9
6
29
-1
23
-6
8
.0
05
.5
86
.0
04
04
1.
23
2
1.
41
8
1.
76
8
N
S
10
18
98
42
C
oe
lia
c
di
se
as
e
C
T
L
A
-4
4-
28
-6
9
21
-4
7-
62
.0
1
.6
55
.0
03
32
1.
86
1
4.
82
4.
53
9
.0
33
10
18
98
42
C
oe
lia
c
di
se
as
e
C
T
L
A
-4
1-
7-
23
16
-3
6-
54
.0
1
.6
74
.0
03
1.
73
1
5.
43
5.
19
8
.0
23
11
88
90
73
C
ol
or
ec
ta
l
ca
nc
er
M
T
H
FR
28
-3
5-
12
20
4-
22
9-
34
.0
5
.3
24
.0
41
5
1.
23
1
1.
99
5
7.
47
8
.0
06
11
88
90
73
C
ol
or
ec
ta
l
ca
nc
er
M
T
H
FR
28
-6
4-
94
11
4-
56
0-
53
3
.0
5
.6
69
.0
45
5
1.
00
0
1.
22
3
10
.1
33
.0
06
11
88
90
73
C
ol
or
ec
ta
l
ca
nc
er
M
T
H
FR
14
-6
6-
73
39
-1
16
-1
48
.0
5
.6
78
.0
43
1
1.
16
1
1.
19
5
4.
31
3
.0
38
10
79
44
88
C
ol
or
ec
ta
l
po
ly
ps
M
T
H
FR
98
-7
2-
26
29
7-
25
8-
71
.0
5
.3
15
.0
48
4
1.
00
0
1.
33
8
4.
32
3
N
S
12
63
16
67
C
ro
hn
di
se
as
e
C
Y
P
1A
1
2-
20
-1
29
5-
22
-1
22
.0
5
.8
79
.0
32
5
1.
00
0
1.
69
8
7.
49
7
.0
24
12
63
16
67
C
ro
hn
di
se
as
e
E
P
X
H
20
-6
0-
71
59
-5
8-
32
.0
5
.4
28
.0
20
1
2.
04
6
6.
30
7
6.
75
9
.0
09
979
12
63
16
69
C
ro
hn
di
se
as
e
N
O
D
2
24
8-
20
-3
29
0-
10
-0
.0
5
.0
20
6
.0
47
8
1.
92
9
20
.7
1
.4
54
N
S
11
40
21
26
D
em
en
ti
a
A
C
E
74
-2
39
-1
20
98
-2
33
-1
44
.1
.5
39
.0
80
8
1.
30
1
1.
30
1
2.
45
7
N
S
12
22
11
64
E
pi
le
ps
y
O
P
R
M
1
19
3-
29
-8
20
8-
20
-0
.0
1
.0
45
1
.0
09
2
1.
59
2
18
.7
19
.3
99
N
S
96
07
20
7
H
yp
er
te
ns
io
n/
ne
ph
ro
an
gi
os
cl
er
os
is
A
C
E
6-
10
-2
1
8-
48
-1
9
.0
5
.5
57
.0
31
2
1.
00
0
2.
93
3
7.
18
.0
28
10
79
23
36
ID
D
M
V
D
R
13
7-
16
-4
23
1-
16
-1
.0
5
.0
46
.0
48
2
1.
23
6
9.
31
5
3.
48
2
N
S
11
23
13
53
ID
D
M
ne
ph
ro
pa
th
y
G
L
U
T
1
3-
29
-1
0
21
-6
0-
23
.0
05
.4
95
.0
01
39
4.
48
2
4.
48
2
3.
60
4
N
S
11
09
72
27
L
un
g
ca
nc
er
H
R
A
S1
17
-8
6-
20
9
21
-1
34
-2
76
.0
1
.7
89
.0
08
82
1.
00
0
1.
21
4
3.
23
9
N
S
11
09
72
27
L
un
g
ca
nc
er
H
R
A
S1
8-
19
-4
9
8-
38
-5
4
.0
1
.7
1
.0
07
42
1.
00
0
1.
69
2
3.
58
3
N
S
11
09
72
27
L
un
g
ca
nc
er
T
P
53
9-
16
-2
6
57
-1
92
-1
97
.0
1
.6
52
.0
08
83
1.
00
0
1.
31
1
4.
33
N
S
11
04
57
85
L
un
g
ca
nc
er
,
sq
ua
m
ou
s
ce
ll
p5
3
16
-4
4-
73
61
-2
12
-2
37
.0
1
.6
68
.0
08
23
1.
00
0
1.
48
3.
48
1
N
S
98
44
14
2
M
ac
ro
an
gi
op
at
hy
PA
I-
1
6-
28
-2
2
22
-8
8-
42
.0
5
.5
67
.0
29
5
1.
68
3
2.
11
6
4.
95
8
.0
26
11
12
23
22
M
yo
ca
rd
ia
l
in
fa
rc
ti
on
A
C
E
18
4-
46
0-
21
7
19
3-
39
3-
21
5
.1
.5
08
.0
88
4
1.
17
4
1.
17
4
1.
74
8
N
S
10
71
24
18
M
yo
ca
rd
ia
l
in
fa
rc
ti
on
T
F-
12
08
22
7-
36
1-
21
8
19
7-
34
9-
18
6
.1
.4
83
.0
95
6
1.
00
0
1.
19
9
6.
50
2
.0
39
10
68
07
82
M
ul
ti
pl
e
sc
le
ro
si
s
G
ST
M
3
27
6-
97
-1
4
22
1-
64
-1
5
.0
5
.1
61
.0
49
6
1.
00
0
1.
33
6
11
.7
22
.0
03
15
33
84
56
d
N
ID
D
M
R
E
T
N
48
-8
5-
16
63
-8
3-
12
.0
54
.3
36
.0
39
6
1.
64
9
1.
64
9
6.
38
4
.0
41
10
23
14
46
N
ID
D
M
ne
ph
ro
pa
th
y
G
L
U
T
1
43
-7
8-
10
77
-4
1-
6
.0
5
.2
19
.0
26
9
3.
19
9
3.
19
9
.0
88
4
N
S
10
23
14
46
N
ID
D
M
ne
ph
ro
pa
th
y
G
L
U
T
1
12
-4
8-
4
77
-4
1-
6
.0
5
.2
19
.0
15
3
6.
81
8
6.
81
8
1.
09
9
N
S
98
44
14
2
N
ID
D
M
ne
ph
ro
pa
th
y
PA
I-
1
64
-1
16
-2
8
66
-8
0-
31
.0
5
.3
88
.0
40
9
1.
35
7
1.
35
7
2.
61
6
N
S
98
44
14
2
N
ID
D
M
ne
ph
ro
pa
th
y
PA
I-
1
28
-5
8-
12
66
-8
0-
31
.0
5
.3
92
.0
38
3
1.
48
4
1.
48
4
2.
74
5
N
S
12
67
58
60
N
ID
D
M
ne
ph
ro
pa
th
y
T
G
F-
b
1
24
-2
4-
17
27
-2
6-
5
.3
.3
54
.2
58
1.
00
0
2.
29
.5
37
N
S
10
96
40
48
O
ra
l
ca
nc
er
C
Y
P
1A
1
96
-3
6-
13
10
4-
54
-6
.0
1
.1
86
.0
09
43
1.
00
0
2.
73
2
1.
63
8
N
S
10
96
40
48
O
ra
l
ca
nc
er
C
Y
P
1A
1
56
-5
5-
31
62
-6
5-
15
.0
1
.3
32
.0
08
7
1.
02
2.
27
5
.0
47
3
N
S
11
91
44
02
Pa
rk
in
so
n
di
se
as
e
N
ur
r1
16
2-
48
-1
5
17
4-
45
-2
.0
2
.1
12
.0
18
3
1.
17
2
5.
82
2
.1
4
N
S
11
78
60
85
R
en
al
pa
re
nc
hy
m
al
sc
ar
ri
ng
T
G
F-
b
1
0-
27
-1
6
16
-7
6-
79
.0
1
.6
69
.0
01
11
.1
1
11
.1
1
3.
97
3
N
S
11
78
60
85
R
en
al
pa
re
nc
hy
m
al
sc
ar
ri
ng
T
G
F-
b
1
13
-2
7-
3
73
-7
2-
26
.0
1
.3
03
.0
05
51
4.
00
1
3.
95
.0
62
7
N
S
10
43
04
41
St
ro
ke
N
O
S3
10
9-
12
5-
31
15
4-
20
3-
36
.1
5
.3
53
.1
5
1.
00
0
1.
00
4
7.
46
6
.0
24
11
02
79
31
V
en
ou
s
th
ro
m
bo
si
s
b
-fi
br
og
en
2-
6-
82
0-
22
-1
63
.0
1
.9
26
.0
08
92
1.
00
0
1.
14
1
9.
55
.0
08
11
02
79
31
V
en
ou
s
th
ro
m
bo
si
s
Fa
ct
or
7
67
-1
9-
5
14
8-
33
-4
.0
1
.1
15
.0
09
4
1.
09
6
4.
35
1
1.
75
8
N
S
12
75
32
58
V
er
te
br
al
fr
ac
tu
re
C
O
L
IA
1
10
-2
-5
75
-3
5-
6
.0
1
.2
.0
07
54
1
9.
12
5
2.
24
N
S
a
ID
D
M
p
in
su
lin
-d
ep
en
de
nt
di
ab
et
es
m
el
lit
us
;
N
ID
D
M
p
no
n–
in
su
lin
-d
ep
en
de
nt
di
ab
et
es
m
el
lit
us
.
b
In
th
e
ge
no
ty
pe
di
st
ri
bu
ti
on
s
fo
r
pa
ti
en
ts
an
d
co
nt
ro
ls
,
th
e
th
re
e
nu
m
be
rs
se
pa
ra
te
d
by
hy
ph
en
s
re
pr
es
en
t
th
e
no
ns
us
ce
pt
ib
le
ho
m
oz
yg
ot
es
,
th
e
he
te
ro
zy
go
te
s,
an
d
th
e
su
sc
ep
ti
bl
e
ho
m
oz
yg
ot
es
.
c
N
S
p
no
t
si
gn
ifi
ca
nt
.
d
O
sa
w
a
et
al
.
(2
00
4)
980 Am. J. Hum. Genet. 76:967–986, 2005
Table 2
Direction of DHW, Given a Genetic Disease Model and
Parameter Values
MODEL
DIRECTION OF DHW IN
Patients Controls
Dominant  
Recessive  
Additive If , ;g ! 2
if , ;g 1 2
if , 0gp 2

Multiplicative 0 
General If , ;2g 1 b
if , 2g ! b
If , ;2g 1 ab 1 2b ag
if , 2g 1 ab ! 2b ag
NOTE.—A plus sign () represents an excess of homo-
zygotes, and a minus sign () represents a deficiency of
homozogyotes.
trols was 311 wt/wt homozygotes, 25 Cins/wt hetero-
zygotes, and 0 Cins/Cins homozygotes, which is consis-
tent with HWE.
If the allele frequencies in both the patients (q pp
) and the controls ( ) are used to help0.082 q p 0.037c
delineate the general genetic disease model that best
fits the observed genotypic distributions, we find that
it can be characterized by , ,K p 0.002 qp 0.0379P
, , and . If a x2 testap 0.00186 bp 1.696 gp 18.338
is performed to determine the goodness-of-fit of the ex-
pected number of patients and controls, given the model
that best fits the observed genotypic counts, 2x p
( with 1 df); thus, the best-fit model is0.478 Pp .827
a good fit to the observed data. Moreover, the model is
consistent with what has been obtained elsewhere for
other types of data (Hampe et al. 2001; Ogura et al.
2001).
Example 2: DHW in Opposite Directions in Patients
and Controls
Ozaki et al. (2002) published a large-scale association
study designed to identify genetic variation affecting risk
of MI in a Japanese sample. The study involved an initial
screen of 192,000 SNPs in a small sample and follow-
up studies for those SNPs with evidence of association
( for a dominant or recessive model) performedP ! .01
in a larger sample (1,133 patients, 1,006 random con-
trols, and 872 age-matched random controls). This led
to more intensive studies of the LTA region (near HLA
on 6p21), with 5 of 26 SNPs genotyped in the region
showing highly significant association with MI (e.g., for
LTA exon 1 polymorphism, ).6Pp 3.3# 10
Although Ozaki et al. (2002) reported that all 26 SNPs
were in HWE, with , we note that each of the 5P 1 .01
SNPs for which genotype distributions are published
show a significant DHW in opposite directions for pa-
tients and controls. The LTA exon 1 polymorphism is
the most significantly associated with MI, with a ge-
notype distribution among the 1,133 patients of 416 GG
homozygotes, 504 GA heterozygtoes, and 213 AA ho-
mozygotes, which yields ( )—an2x p 7.40 Pp .0065
excess of homozygotes relative to HWE-expected ge-
notype proportions. The genotype distribution among
the 1,006 random controls is 378 GG homozygotes, 512
GA heterozygotes, and 116 AA homozygotes. This sam-
ple of controls generates ( ) but2x p 8.51 Pp .0035
shows a deviation in the opposite direction of patients,
with a deficiency of homozygotes. The age-matched ran-
dom control group of 872 individuals has a genotype
distribution of 344 GG homozygotes, 428 GA hetero-
zygotes, and 100 AA homozygotes, corresponding to a
nonsignificant ( ) but also showing2x p 3.69 Pp .055
a deficiency of homozygotes similar to that seen for the
1,006 random controls.
The first problem easily identified is that a significant
DHW is observed in a sample that may be better char-
acterized as a random sample than a control sample
and thus would not be expected to show DHW, regard-
less of the underlying genetic disease model. If we as-
sume that the control sample is a control sample, rather
than a random sample, the best-fit model is ,K p 0.01P
, , , and .qp 0.371 ap 0.00932 bp 1.024 gp 1.469
The goodness-of-fit to the observed data is significantly
poor, with ( with 1 df). Given that2x p 5.024 Pp .025
the best-fit model is not a good fit to what is observed
in the 1,133 patients and 1,006 controls, the underlying
genetic disease model for a susceptibility locus in that
region is therefore an unlikely explanation for the ob-
served DHW.
Survey of DHW
We identified 41 association studies with 60 poly-
morphisms that depart from HWE, from several recent
reviews (Xu et al. 2002; Gyo¨rffy et al. 2004; Kocsis et
al. 2004a, 2004b; Osawa et al. 2004) (table 1). All KP
values were either given by the association study or were
identified on the World Health Organization Web site.
There are 35 polymorphisms that depart from HWE in
patients only, 21 that depart in controls only, 2 that
depart in the same direction in patients and controls,
and 1 that departs in the opposite direction in patients
and controls. Of those that have a dominant or recessive
model as the best-fit genetic model, 35.3% (12 of 34)
did not have a genetic model that fit the observed ge-
notype distributions. Of those for which the best-fit
model was a general model, 53.8% (14 of 26) did not
have a model that fit well the observed data. Therefore,
43.3% of the polymorphisms we identified from the re-
views are inconsistent with a biological reason for the
observed DHW. This highlights the importance not only
of correctly assessing HWE for genotype data but also
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of understanding whether an observed DHW is consis-
tent with a genetic model of disease susceptibility.
Discussion
Investigators have taken surprisingly inconsistent path-
ways in the interpretation and use of DHW. In some
cases, investigators report significant association be-
tween variation at candidate genes and complex disor-
ders that is quite dependent on the existence of DHW
(i.e., the associations are genotypic rather than allelic,
and the genotypic differences are driven by DHW). In
at least some situations, the observed DHW is implau-
sible from a biological perspective, which calls into ques-
tion the association result. On the other hand, some
investigators believe that any marker showing a DHW
is likely to be erroneous and/or misleading; as a result,
they may be throwing away information valuable for
mapping and identifying causal polymorphisms. With
the analytic framework and software we have developed,
we provide a way for investigators to assess markers
with DHW in a more logical and systematic way by
distinguishing those that could be attributed to the un-
derlying genetic model at the susceptibility locus from
those due to genotyping errors, chance, and/or violations
of the assumptions of HWE, thereby improving the qual-
ity of scientific inferences.
Given the increasing sample sizes contemplated for
large-scale association studies, it would seem that DHW
is a neglected and potentially fruitful avenue for further
research to improve signal localization. Results of stud-
ies of the CARD15/NOD2 region provide support for
this notion. A common coding polymorphism (P268S)
( in patients with Crohn disease, andqp 0.35 qp
in unaffected controls) shows significant DHW,0.29
with an excess of homozygotes in both Jewish patients
( ) and in patients overall ( ) (J.Pp .0277 Pp .00546
Cho, personal communication). The best-fit model for
this polymorphism provides a good fit to the observed
genotypic distributions ( ;2 10x p 1.501# 10 Pp 1.0
with 1 df). Although this polymorphism is not thought
to affect the risk of Crohn disease, three of the known
susceptibility alleles (Leu3020fsinsC, Gly908Arg, and
Arg702Trp) are in the same haplotype as the more rare
allele at this site. If patients with any of those mu-
tations are removed from the patient population and
HWE is reassessed, the DHW is no longer significant
( for Jewish patients, and for pa-Pp .2115 Pp .632
tients overall). If none of the causative SNPs had been
previously identified, the observation that the com-
mon polymorphism departed from HWE in a way that
was consistent with a genetic model could have been
used to support further investigation of the local region.
This observation highlights the value of using DHW
when fine mapping complex diseases, as originally hy-
pothesized by Nielsen et al. (1998).
Given the relatively large sample sizes used in modern
candidate-gene studies as well as in fine-mapping and
positional cloning studies, and the fact that DHW
should be expected for a wide range of genetic disease
models (consistent with the modest genetic contribu-
tions likely to be relevant for complex disorders), it is
perhaps surprising that we have not seen a larger num-
ber of markers reported to show DHW. Of 60 SNPs
from association studies in which DHW has been iden-
tified in patients and/or controls and in which both pa-
tient and control genotype distributions are available,
34 (56.7%) have genotype distributions consistent with
the expectations from a best-fit model (table 1). DHW
in patients is never expected for a multiplicative model
and is less likely to be detected as significant for a model
with susceptibility-allele frequencies at the tails of the
frequency spectrum. We have not examined the con-
sequences for HWE in more-complex disease models
with allelic or locus epistasis, profound sex effects, etc.,
and, if such models were standard for complex disor-
ders, it is unclear what the consequences would be.
Thus, the failure to more often observe DHW at poly-
morphisms hypothesized to affect susceptibility to com-
plex disorders may reflect biological characteristics of
the genetic disease model that make such DHW im-
possible or at least less likely.
It is also possible that investigators mistrust data with
DHW and may sometimes ignore such polymorphisms
with DHW in their studies. Systematic errors in geno-
typing or nonrandom patterns of missing data may gen-
erate a relatively consistent pattern of DHW (e.g., dis-
proportionate missing data in heterozygotes may lead
to a consistent pattern of DHW, with an excess of ho-
mozygotes). Other types of error may be more sporadic.
An unrecognized polymorphism in primer sequences
used in subsequent PCR may lead to DHW, with an
excess of homozygotes, particularly when the primer
polymorphism is in LD with one of the test alleles. Ge-
nomic duplications or deletions can also lead to DHW.
Because even the systematic errors will not be universal,
error and nonrandom patterns of missing data may be
detectable in a single marker within a set that are in
strong LD. In contrast, when markers have DHW due
to violations of assumptions of HWE or to chance,
markers in LD may show similar patterns of DHW.
Independent samples will tend not to replicate chance
DHW but may replicate DHW due to violations of
HWE assumptions. Clearly, genomewide or large-scale
studies offer additional information for interpretation
of DHW, including, for example, the ability to examine
potential population substructure. Many of the studies
summarized in table 1, however, focus on one or a small
number of candidate genes, and the approaches we pro-
pose offer a unique opportunity to improve the scientific
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inferences about observed DHW. It should also be noted
that just because an observed DHW is consistent with
genetic models does not mean that errors, missing data
patterns, or violations of HWE assumptions did not
generate or contribute to the observed DHW, and DHW
can no doubt be attributable to a combination of fac-
tors. Finally, it should also be noted that investigators
frequently underestimate the significance of observed
DHW, probably because of a misunderstanding of the
degrees of freedom associated with the test.
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Appendix A
D in Patients
Weir (1996) defines D as the difference between the population and HWE-expected genotypic frequencies. There-
fore, we first define these genotypic frequencies in terms of q, the susceptibility-allele frequency in the general
population; a, the baseline penetrance for wild-type homozgyotes; b, the relative risk to heterozygotes; g, the relative
risk to homozygotes for the susceptibility allele; and KP, the population prevalence of disease. The expected genotypic
proportions in patients, under the assumption of HWE in the general population, are as follows:
2 2(1 q) a 2q(1 q)ab q ag
g p , g p , and g p .AA Aa aaK K KP P P
The expected susceptibility-allele frequency for patients is
2q ag q(1 q)ab
q p .p KP
The frequency of the wild-type allele in patients is
2(1 q) a q(1 q)ab
p p 1 q p .p p KP
Therefore,
2 2 2(1 q) a [(1 q) a q(1 q)ab]2D p g  (1 q ) p  ,p AA p 2K KP P
which then simplifies to equation (1).
For a classic recessive model, where and ,bp 1 g 1 1
2 2q (1 q) (g 1)
D p .p 2 2 2(1 q  q g)
For a classic dominant model, where and ,bp g g 1 1
2 2 2q (1 q) (g g )
D p .p 2 2 2[(1 q)  2qg q g]
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For an additive model, where and ,gp 2b b 1 1
2g2 2q (1 q) g( )
4
D p .p 2 2[(1 q)  qg]
As explained in the “Methods” section, the multiplicative model for patients, where and , simplifies2b p g b 1 1
to .D p 0p
Appendix B
D in Controls
As defined for patients in appendix A, we define the genotypic proportions in controls for a general disease
model as
2 2(1 q) (1 a) 2q(1 q)(1 ab) q (1 ag)
g p , g p , g p .AA Aa aa1 K 1 K 1 KP P P
The expected susceptibility-allele frequency in controls is
2q (1 ag) q(1 q)(1 ab)
q p .c 1 KP
The frequency of the wild-type allele in controls is
2(1 q) (1 a) q(1 q)(1 ab)
p p 1 q p .c c 1 KP
Therefore,
2 2 2(1 q) (1 a) [(1 q) (1 a) q(1 q)(1 ab)]2D p g  (1 q ) p  ,c AA c 21 K (1 K )P P
which simplifies to equation (2).
For a classic recessive model, where and ,bp 1 g 1 1
2 2aq (1 q) (1 g)(1 a)
D p .c 2(1 K )P
For a classic dominant model, where and ,bp g g 1 1
2 2 ( )aq (1 q) (1 ag) g 1
D p .c 2(1 K )P
For an additive model, where and ,gp 2b b 1 1
2ag2 2aq (1 q) ag1( )4
D p .c 2(1 K )P
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Finally, for a multiplicative model, where and ,2gp b b 1 1
2 2 2aq (1 q) ( g 1)
D p .c 2(1 K )P
Appendix C
ls Values
Given that
1 1 1
l p 1 V  Vs A D2( ) ( )K 2 4P
(Risch 1990), where VA is the additive variance that can be calculated by
2V p 2pq[p(a ab) q(ab ag)]A
and VD is the dominance variance that can be calculated by
2 2 2V p p q (ag a 2ab) ,D
ls under the classic dominant model can then be calculated as
12 2 2 2pq[p(a ag)]  [p q (a ag) ]
4
l p 1 ,s 2KP
ls under the classic recessive model can be calculated as
12 2 2 2pq[q(a ag)]  [p q (ag a) ]
4
l p 1 ,s 2KP
ls under the additive model can be calculated as
2
ag 1 2 2 2( )pq a  qa  p q a ag( )2 4
l p 1 ,s 2KP
and, finally, ls under the multiplicative model can be calculated as
12 22 2  pq p aa g q a g ag  p q aga2a g[ ( ) ( )] ( )
4
l p 1 .s 2KP
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Appendix D
Goodness-of-Fit Test
The expected genotypic proportions for patients under a genetic disease model are gAA-p, gAap, and gaa-p, as found
in appendix A. The expected genotypic proportions for controls under a genetic disease model are gAA-c, gAa-c, and
gaa-c, as found in appendix B.
For a particular set of disease model parameter values (a, b, g, and q), where the total number of patients is
Np, the total number of controls denoted is Nc, and the observed number of patients (or controls), given a specific
genotype, is Ngenotype-p (or Ngenotype-c), the goodness-of-fit test is as follows:
2 2 2(N g N ) (N g N ) (N g N )p AA-p AA-p p Aa-p Aa-p p aa-p aa-p2x p  
N g N g N gp AA-p p Aa-p p aa-p
2 2 2(N g N ) (N g N ) (N g N )c AA-c AA-c c Aa-c Aa-c c aa-c aa-c   .
N g N g N gc AA-c c Aa-c c aa-c
Minimizing the resulting test statistic over the entire parameter space, subject to appropriate constraints on a, b,
g, and q and where KP is fixed, yields parameter estimates that are approximately maximum-likelihood estimates.
The minimal value of the test statistic is approximately distributed as a x2 with 1 df for a general model and 2 df
for restricted models (i.e., dominant, recessive, additive, and multiplicative models) (Cramer 1946). We verify
through simulations that applying this test to data showing a DHW does not affect the resulting distribution of
the test statistic. We generated 1,000 replicates of 1,000 patients and 1,000 controls under a dominant, recessive,
or general disease model as specified by the penetrances, which offer an advantage in being bound between 0 and
1. We kept for further analysis only replicates that showed DHW in patients, in controls, or in both patients and
controls. We used the goodness-of-fit test to find the best-fit genetic model for each simulation and compared the
resulting x2 value to 1,000 simulated x2 values, given the specified degrees of freedom (fig. 5).
If the goodness-of-fit test, with 1 df for a general model or 2 df for a restrictive model, corresponds to a P value
less than the specified threshold, the genetic disease model can be rejected as a poor fit to the observed data. Note
that rare-allele frequencies, which may produce low genotype counts, may produce approximations from the
goodness-of-fit test that do not perform as expected.
Figure 5 Simulations with the goodness-of-fit test. The legend
is available in its entirety in the online edition of The American Journal
of Human Genetics.
Electronic-Database Information
The URLs for data presented herein are as follows:
DHW software, http://hg-wen.uchicago.edu/dhw2.html
World Health Organization, http://www.who.int/en/
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